Global Amniotic Membrane Market Poised for Extraordinary Growth at a CAGR of ~7% by 2032 | DelveInsight

The amniotic membrane market is experiencing notable expansion, fueled by several contributing factors. The growing incidence of chronic wounds, including burns and traumatic injuries, is driving the demand for advanced wound healing treatments. Moreover, the increasing prevalence of eye conditions such as dry eye and keratitis is broadening the application of amniotic membranes in ophthalmology. These healthcare needs, combined with strong research and development efforts by leading companies, are fostering innovation and enhancing adoption rates, ultimately propelling the growth of amniotic membrane-based therapies.

New York, USA, July 30, 2025 (GLOBE NEWSWIRE) -- Global Amniotic Membrane Market Poised for Extraordinary Growth at a CAGR of ~7% by 2032 | DelveInsight

The amniotic membrane market is experiencing notable expansion, fueled by several contributing factors. The growing incidence of chronic wounds, including burns and traumatic injuries, is driving the demand for advanced wound healing treatments. Moreover, the increasing prevalence of eye conditions such as dry eye and keratitis is broadening the application of amniotic membranes in ophthalmology. These healthcare needs, combined with strong research and development efforts by leading companies, are fostering innovation and enhancing adoption rates, ultimately propelling the growth of amniotic membrane-based therapies.

DelveInsight’s Amniotic Membrane Market Insights report provides the current and forecast market analysis, individual leading amniotic membrane companies’ market shares, challenges, amniotic membrane market drivers, barriers, trends, and key market amniotic membrane companies in the market.

Key Takeaways from the Amniotic Membrane Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global amniotic membrane market during the forecast period. 
• In the type segment of the amniotic membrane market, the devices category accounted for the largest market share in 2024. 
• Notable amniotic membrane companies such as BioTissue, Inc., Corza Ophthalmology, Integra LifeSciences, Merakris Therapeutics, Inc., Seed Biotech, Inc., Atlas Ocular, BioLab Holdings, Inc., Orthofix Medical Inc., Labtician Ophthalmics Inc., Smith & Nephew, Organogenesis Inc., Celularity Inc., Tides Medical, StimLabs, MIMEDX Group, Inc., NuVision Biotherapies Ltd., Next Biosciences, Sanara MedTech Inc., Axogen Corporation, Dynamic Medical Services DBA Acesso Biologics, and several others are currently operating in the amniotic membrane market.
• In April 2025, BioTissue Inc. announced that the new research will be presented at the 2025 American Urological Association Conference in Las Vegas, which evaluated robotic ureteral reconstruction using Clarix® 1K, an ultra-thick cryopreserved amniotic membrane by BioTissue Surgical. In a study of 17 patients, 88% showed symptomatic improvement and 76% had radiographic improvement at one-year follow-up. Researchers concluded that Clarix® 1K was a safe and effective alternative to autologous grafts for medium-length ureteral strictures.
• In November 2024, Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island.
• In October 2024, Merakris Therapeutics launched Dermacyte AC Matrix, a lyophilized amnion-chorion membrane allograft, at the Fall Symposium for Advanced Wound Care in Las Vegas. The product featured multiple membrane layers and an optimized bioprocess, offering better protein retention and maintaining key physical and biological properties of placental membranes.
• In June 2024, BioTissue Inc. launched CAM360 AG, a hydrated, shelf-stable cryopreserved amniotic membrane, as a ringless, no-refrigeration solution ideal for mild to moderate dry eye and ocular surface conditions. Its adhesive properties helped it stay in place under a bandage contact lens, enhancing comfort and treatment.
• In June 2024, Axogen, Inc. launched Avive+ Soft Tissue Matrix™, a resorbable, multi-layer amniotic membrane allograft designed as a soft tissue barrier for peripheral nerve healing. The product was processed and distributed in compliance with FDA and state regulations as a 361 human tissue product.

To read more about the latest highlights related to the amniotic membrane market, get a snapshot of the key highlights entailed in the Global Amniotic Membrane Market Report

Amniotic Membrane Overview

The amniotic membrane is the innermost layer of the placenta, consisting of a thin yet resilient sheet of tissue that surrounds and protects the developing fetus during pregnancy. It is composed of a single layer of epithelial cells, a basement membrane, and an avascular stromal matrix rich in collagen and growth factors. Due to its unique biological properties, the amniotic membrane plays a crucial role in promoting fetal development by providing a protective barrier against infections, regulating fluid exchange, and supporting cell growth and differentiation. Its natural anti-inflammatory, anti-scarring, and antimicrobial properties make it an important biological material in regenerative medicine.

In clinical practice, amniotic membranes are widely used in ophthalmology, dermatology, and wound care for their healing and tissue-repairing capabilities. Processed amniotic membrane grafts are employed to treat corneal defects, chronic ulcers, burns, and surgical wounds, where they promote epithelialization, reduce inflammation, and minimize fibrosis. Additionally, research is exploring its potential applications in orthopedic, dental, and reconstructive surgeries. The membrane can be used fresh, cryopreserved, or dehydrated, depending on the medical application, and its immunologically privileged nature allows it to be used safely in allogeneic transplantation without provoking significant immune responses.

Amniotic Membrane Market Insights

North America dominated the amniotic membrane market in 2024, driven by several critical factors. The increasing incidence of chronic wounds and eye-related disorders is a key driver of market growth. Moreover, the region benefits from a well-established healthcare infrastructure and a strong presence of major industry players, which fosters product innovation and development, further propelling market expansion.

In the U.S., the market is also bolstered by continuous innovation from leading companies. For instance, in July 2023, Celularity Inc. partnered with Verséa Health, Inc. through an exclusive U.S. commercialization agreement. Under this deal, Verséa distributed Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products—single- and triple-layer amniotic membrane allografts designed to aid in the treatment of ocular surface diseases and support surgical procedures. The BIOVANCE® 3L Ocular, a cell-free product, offers tissue protection and helps maintain tissue structure during healing.

These factors combined are anticipated to substantially contribute to the growth of the amniotic membrane market in North America over the forecast period of 2025 to 2032.

To know more about why North America is leading the market growth in the amniotic membrane market, get a snapshot of the Amniotic Membrane Market Outlook

Amniotic Membrane Market Dynamics

The amniotic membrane market is witnessing steady growth, driven by a combination of rising clinical demand, technological advancements, and expanding therapeutic applications. Increasing incidences of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and burns are significant growth drivers, as the amniotic membrane has demonstrated efficacy in promoting wound healing, reducing inflammation, and minimizing scarring. Additionally, its use in ophthalmology, particularly in treating ocular surface disorders like dry eye disease, keratitis, and corneal ulcers, has expanded considerably. These factors, combined with the membrane's anti-inflammatory, anti-fibrotic, and antimicrobial properties, are propelling clinical adoption.

From a technological standpoint, companies in the space are innovating in product preservation techniques such as cryopreservation, lyophilization, and dehydrated amniotic membranes, enhancing shelf life and clinical usability. Moreover, the development of easy-to-use products like amniotic membrane patches, injectables, and sheets is improving clinician convenience and broadening the product's application across multiple specialties, including orthopedics, dentistry, and plastic surgery. Regulatory approvals in major markets like the U.S. and Europe have further validated the safety and efficacy of these products, fostering market penetration.

However, the market is not without challenges. High costs associated with the processing and preservation of amniotic membranes, coupled with reimbursement uncertainties in some regions, may limit access to these advanced therapies. Ethical concerns and stringent regulations governing tissue donation and processing also present barriers to rapid market expansion. Additionally, competition from alternative wound healing and regenerative therapies, such as stem cells, growth factors, and synthetic matrices, creates a dynamic but competitive landscape.

Looking ahead, the amniotic membrane market is poised for sustained growth, driven by increasing investments in regenerative medicine, expanding clinical research demonstrating broader therapeutic utility, and growing awareness among healthcare providers and patients. Emerging markets in Asia-Pacific and Latin America, where healthcare infrastructure is improving and chronic wound burden is rising, present untapped growth opportunities. Strategic collaborations, mergers, and acquisitions among biotechnology companies, hospitals, and tissue banks will further shape the competitive dynamics of this evolving market.

Get a sneak peek at the amniotic membrane market dynamics @ Amniotic Membrane Market Trends 

Amniotic Membrane Market Assessment

• Amniotic Membrane Market Segmentation
  • Amniotic Membrane Market Segmentation By Type: Dehydrated Amniotic Membranes and Cryopreserved Amniotic Membranes
  • Amniotic Membrane Market Segmentation By Route of Application: Surgical Wounds, Ophthalmic Disorders, and Others
  • Amniotic Membrane Market Segmentation By End-User: Hospitals, Ambulatory Surgical Centres, and Others
  • Amniotic Membrane Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the amniotic membrane market are set to emerge as the trendsetter explore @ Amniotic Membrane Analysis

Table of Contents 

Interested in knowing the amniotic membrane market by 2032? Click to get a snapshot of the Amniotic Membrane Market Analysis

Related Reports

Dry Eye Disease Market

Dry Eye Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dry eye disease companies, including Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, AxeroVision, Inc., AxeroVision, Inc., Glaukos Corporation, Oculis, among others.

Keratitis Market

Keratitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key keratitis companies, including Cipla, Mylan Pharma, Bausch & Lomb, Vectans Pharma, Aurobindo Pharma, GlaxoSmithKline, Jubilant Cadista, Dr. Reddy's Laboratories, among others.

Corneal Ulcer Market

Corneal Ulcer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key corneal ulcer companies, including OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas Medicine, among others.

Glaucoma Market

Glaucoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Santen Pharmaceutical, Omikron Italia S.r.l., OPIS Spain, Tarsier Pharma, Qlaris Bio, Inc., D. Western Therapeutics Institute (DWTI), MediPrint Ophthalmics (formerly Leo Lens Pharma), Peregrine Ophthalmic, VivaVision Biotech, Inc., among others.

Cataracts Market

Cataracts Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cataracts companies, including Nacuity Pharmaceuticals, CGeneTech, Plex Pharmaceuticals, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.